WESTLAKE VILLAGE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its first quarter 2015 operating results and will host an investor call and webcast at 4:30 p.m. ET on Thursday, May 7, 2015.
Individuals interested in participating in the call should dial (877) 344-3890 (U.S. and Canada) or (760) 666-3770 (international) using conference ID number 28863520. To access the webcast, please visit the Investors section of KYTHERA's website at www.kythera.com.
The call will be available for replay via telephone starting May 7, 2015, at approximately 5:30 p.m. ET, running through 11:59 p.m. ET on May 13, 2015. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 28863520. The archived webcast will be available on KYTHERA's website for seven days beginning approximately one hour after the call has completed.
About KYTHERA®
KYTHERA Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Its lead product, KYBELLA™ (deoxycholic acid) is the first and only approved injectable drug for contouring moderate to severe submental fullness, a condition that is commonly referred to as a double chin. KYTHERA also licensed the worldwide rights to setipiprant (KYTH-105), an early-stage potential treatment for hair loss. KYTHERA's longer-term strategy is to leverage its biotechnology and aesthetics experience to expand its product portfolio and pipeline. KYTHERA has submitted regulatory filings for ATX-101 in Canada, Switzerland and Australia. Find more information at www.kythera.com.